問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiology

Division of Urology

更新時間：2023-09-19

鍾孝仁Chung, Hsiao-Jen
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

54Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鍾孝仁

List

105Cases

2015-12-08 - 2018-08-30

Phase II

A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone

  • Condition/Disease

    castration-resistant prostate cancer, CRPC

  • Test Drug

    BI 836845

Participate Sites
4Sites

Terminated4Sites

2015-07-01 - 2023-10-27

Phase III

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Nivolumab (BMS-936558)

Participate Sites
3Sites

Terminated3Sites

黃逸修
Taipei Veterans General Hospital

Division of Hematology & Oncology

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-04-01 - 2024-01-10

Phase III

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL

Participate Sites
6Sites

Recruiting6Sites

2013-09-30 - 2017-10-31

Phase III

A Phase III, randomised, double-blind, placebo-controlled study of tasquinimod in Asian chemo-naïve patients with metastatic castrate resistant prostate cancer.

  • Condition/Disease

    metastatic castrate resistant prostate cancer

  • Test Drug

    Tasquinimod

Participate Sites
5Sites

Terminated5Sites

2007-10-31 - 2011-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB